Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease
Arman Qamar, Elliott M. Antman, Christian T. Ruff, Francesco Nordio, Sabina A. Murphy, Laura T. Grip, Norton J. Greenberger, Ophelia Q.P. Yin, Youngsook Choi, Hans J. Lanz, Michele F. Mercuri, Eugene Braunwald and Robert P. Giugliano
Edoxaban in AF and History of Liver Disease in the ENGAGE-AF TIMI 48 Trial
There were no significant differences in the peak and trough % inhibition in endogenous factor Xa activity relative to baseline with higher-dose edoxaban regimen in patients with versus without liver disease (A). A history of liver disease did not alter the relative efficacy and safety of edoxaban compared to warfarin (B). All values for inhibition in endogenous FXa activity are reported as median (interquartile range). AF = atrial fibrillation; ENGAGE AF-TIMI 48 = Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis In Myocardial Infarction 48; HDER = higher-dose edoxaban regimen; p-int = interaction p value.